Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Rousselot

Showing results (1-10 of 195) with videos related to

Pageof 20
Sort By:
Blood|February 1, 2024
Old rivals become new friendsPhilippe Rousselot
La Revue Du Praticien|December 13, 2005
[Diagnosis and treatment of chronic myelogenous leukemia]Philippe Rousselot
Leukemia & Lymphoma|June 19, 2018
The story of tyrosine kinase inhibitors discontinuation in clinical practicePhilippe Rousselot
Blood|February 18, 2021
BiTtEn by Src inhibitorsPhilippe Rousselot
Blood|March 13, 2025
Why is InO's divine veil not protective against resistance?Philippe Rousselot
Blood|May 23, 2024
The stepbrothers of ABLSON have their own sensitivityPhilippe Rousselot
The Lancet. Haematology|December 15, 2021
Matchpoint: the game is not over for blast-phase chronic myeloid leukaemiaPhilippe Rousselot
Bulletin Du Cancer|November 25, 2022
[New drug approval: Asciminib for the treatment of adult patients with Ph+ CML previously treated with two or more tyrosine kinase inhibitors]Gaëlle Rey, Philippe Rousselot
Drugs & Aging|September 15, 2011
Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderlyPhilippe Rousselot, André Delannoy
The New England Journal of Medicine|June 3, 2026
Chronic Myeloid Leukemia in Low- and Middle-Income CountriesFrançois-Xavier Mahon, Delphine Réa, Philippe Rousselot
Pageof 20

Showing results (1-10 of 195) with videos related to

Sort By:
Pageof 20
Blood|February 1, 2024
Old rivals become new friendsPhilippe Rousselot
La Revue Du Praticien|December 13, 2005
[Diagnosis and treatment of chronic myelogenous leukemia]Philippe Rousselot
Leukemia & Lymphoma|June 19, 2018
The story of tyrosine kinase inhibitors discontinuation in clinical practicePhilippe Rousselot
Blood|February 18, 2021
BiTtEn by Src inhibitorsPhilippe Rousselot
Blood|March 13, 2025
Why is InO's divine veil not protective against resistance?Philippe Rousselot
Blood|May 23, 2024
The stepbrothers of ABLSON have their own sensitivityPhilippe Rousselot
The Lancet. Haematology|December 15, 2021
Matchpoint: the game is not over for blast-phase chronic myeloid leukaemiaPhilippe Rousselot
Bulletin Du Cancer|November 25, 2022
[New drug approval: Asciminib for the treatment of adult patients with Ph+ CML previously treated with two or more tyrosine kinase inhibitors]Gaëlle Rey, Philippe Rousselot
Drugs & Aging|September 15, 2011
Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderlyPhilippe Rousselot, André Delannoy
The New England Journal of Medicine|June 3, 2026
Chronic Myeloid Leukemia in Low- and Middle-Income CountriesFrançois-Xavier Mahon, Delphine Réa, Philippe Rousselot
Pageof 20